Gefitinib (INN /ɡɛˈfɪtɨnɪb/ trade name Iressa marketed by AstraZeneca and Teva) is a drug used for certain breast lung and other cancers. Gefitinib is an EGFR inhibitor like erlotinib which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore it is only effective in cancers with mutated and overactive EGFR.
This page contains content from the copyrighted Wikipedia article "Gefitinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
